Pacific Biosciences of California - PACB Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PACB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PACB, but not buy additional shares or sell existing shares.
View PACB analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12 month target prices for Pacific Biosciences of California's shares. Their PACB share price forecasts range from $8.00 to $14.00. On average, they anticipate the company's stock price to reach $11.50 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

Pacific Biosciences of California's stock was trading at $8.18 on January 1st, 2023. Since then, PACB stock has increased by 17.1% and is now trading at $9.58.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PACB earnings forecast.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings data on Thursday, February, 16th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. The biotechnology company had revenue of $27.35 million for the quarter, compared to the consensus estimate of $27.29 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 47.73% and a negative net margin of 244.93%. The firm's revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.30) earnings per share.

ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Global X Telemedicine & Digital Health ETF (EDOC), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), AltShares Event-Driven ET (EVNT), Principal Healthcare Innovators ETF (BTEC) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Pacific Biosciences of California issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.30 million-$27.30 million, compared to the consensus revenue estimate of $27.88 million.

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.36%), Jackson Square Partners LLC (6.64%), Sumitomo Mitsui Trust Holdings Inc. (6.27%), Nikko Asset Management Americas Inc. (6.27%), T. Rowe Price Investment Management Inc. (2.68%) and Point72 Asset Management L.P. (2.36%). Insiders that own company stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends.

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PACB stock can currently be purchased for approximately $9.58.

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.37 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

The company employs 728 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.